Sleep Disorders and Tumor Immune Microenvironment

Condition(s) studied

Investigational drug(s) / intervention(s)

PSQI: PSQI

Study summary

Title: Impact of Sleep Disorders on Tumor Immune Microenvironment and Clinical Outcomes in Lung Cancer: A Prospective Cohort Study

Objective:

This prospective study aims to investigate the causal relationship between sleep disorders (e.g., insomnia, obstructive sleep apnea \[OSA\]) and alterations in the tumor immune microenvironment (TIME) in lung cancer patients, and to evaluate their joint effects on immunotherapy response and long-term prognosis.

Study Design:

Prospective observational cohort study with 3-year follow-up. Participants: Newly diagnosed primary lung cancer patients (NSCLC/SCLC) prior to treatment initiation (n = 400, target sample size\*).

Exposure Groups: Stratified by sleep disorder status (confirmed via polysomnography \[OSA\] and validated questionnaires \[e.g., PSQI ≥7 for insomnia\]).

Eligibility

Primary outcome measure(s)

• TTP — Baseline: Immune indicators assessed at initial diagnosis (pre-treatment)

Trial sites (1)

More Shanghai Zhongshan Hospital trials in China